Abstract
Objective: This research aimed to determine the most effective dosages and achieve improved outcomes without surgical intervention, discomfort, or blood loss. Its objective was also to regulate the formation of both benign and malignant tumours and reduce tumour size. Patients and Methods: A study involving 50 patients at Dr. Saad Al-Witry Hospital for Neurosciences and Al-Altaj Hospital examined brain tumours using MRI models, CBCT, and a gamma knife device. Patients with large tumours were included, while those receiving single fractions of treatment and pregnant women were excluded. Patients were prepared using Leksell frames, thermoplastic masks, and personalised stereotactic masks. Gamma Knife radiosurgery sessions were administered based on tumour size, location, and patient tolerance. Results: This study analysed the use of hypofractionation gamma knife treatment for six brain tumours: Meningioma, Glioma, Schwannoma, Arteriovenous Malformations (AVM), Pituitary Adenoma, and Metastasis. The mean dose distribution was higher in metastasis, followed by AVM, meningioma, glioma, schwannoma, and pituitary adenoma. The maximum dose was found in metastasis, followed by meningioma, glioma, pituitary adenoma, AVM, and schwannoma. The coverage of the target reached excellent value for metastasis, followed by AVM and pituitary adenoma. The beam on time for the treatment was highest in meningioma. Following six months of treatment, the study found a significant difference in tumour volume before and after six months. The highest reduction was observed in meningioma cases, followed by glioma and vestibular schwannoma. A study involving ten patients showed a significant reduction in tumours after a year of gamma knife treatment, with meningioma cases showing the highest reduction. Conclusion: The study found that metastasis was the most common cancer, followed by meningioma, glioma, schwannoma, AVM, and schwannoma. After six months, meningioma showed the highest reduction, and meningioma showed a better response to hypofractionation, followed by AVM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.